Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia
ABSTRACT Background Cell-free (cf)-DNA, from cellular sources, including Neutrophil Extracellular Traps (NETs), is found in the circulation of COVID-19 patients and may contribute to immune dysregulation. This study determined whether pulmonary administration of the endonuclease, dornase alfa, reduced systemic inflammation by degrading local and systemic cf-DNA.Methods Eligible patients were randomized (3:1) to receive twice-daily nebulised dornase alfa in addition to best available care (BAC) or BAC alone for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was improvement in C-reactive protein (CRP) over time, analysed using a repeated-measures mixed model, adjusted for baseline factors.Results Between June 2020-October 2021 we recruited 39 evaluable patients: 30 randomised to dornase alfa (R-BAC+DA); 9 randomised to BAC (R-BAC); with the addition of 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9mg/L to 23.23 mg/L in the BAC+ dornase alfa group versus a fall from 99.5mg/L to 34.82 mg/L in the T-BAC group at 7 days; P=0.01. This effect of dornase alfa on CRP was confirmed with subgroup and sensitivity analyses that mitigated potential biases associated with the use of the CC-BAC group. Dornase alfa increased the chance of live discharge by 63% (HR 1.63, 95% CI 1.01 to 2.61, P=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, P=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, P=0.004).Conclusion We provide proof-of-concept evidence that dornase alfa reduces pathogenic inflammation in hospitalised patients with COVID-19 pneumonia, suggesting that best available care can be improved by the inclusion of anti-inflammatory treatments that target damage-associated molecules..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 19. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Porter, Joanna C. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.04.14.22272888 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035760559 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035760559 | ||
| 003 | DE-627 | ||
| 005 | 20240120090252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.04.14.22272888 |2 doi | |
| 035 | |a (DE-627)XBI035760559 | ||
| 035 | |a (biorXiv)10.1101/2022.04.14.22272888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Porter, Joanna C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-inflammatory therapy with nebulised dornase alfa for severe COVID-19 pneumonia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background Cell-free (cf)-DNA, from cellular sources, including Neutrophil Extracellular Traps (NETs), is found in the circulation of COVID-19 patients and may contribute to immune dysregulation. This study determined whether pulmonary administration of the endonuclease, dornase alfa, reduced systemic inflammation by degrading local and systemic cf-DNA.Methods Eligible patients were randomized (3:1) to receive twice-daily nebulised dornase alfa in addition to best available care (BAC) or BAC alone for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was improvement in C-reactive protein (CRP) over time, analysed using a repeated-measures mixed model, adjusted for baseline factors.Results Between June 2020-October 2021 we recruited 39 evaluable patients: 30 randomised to dornase alfa (R-BAC+DA); 9 randomised to BAC (R-BAC); with the addition of 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9mg/L to 23.23 mg/L in the BAC+ dornase alfa group versus a fall from 99.5mg/L to 34.82 mg/L in the T-BAC group at 7 days; P=0.01. This effect of dornase alfa on CRP was confirmed with subgroup and sensitivity analyses that mitigated potential biases associated with the use of the CC-BAC group. Dornase alfa increased the chance of live discharge by 63% (HR 1.63, 95% CI 1.01 to 2.61, P=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, P=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, P=0.004).Conclusion We provide proof-of-concept evidence that dornase alfa reduces pathogenic inflammation in hospitalised patients with COVID-19 pneumonia, suggesting that best available care can be improved by the inclusion of anti-inflammatory treatments that target damage-associated molecules. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Inshaw, Jamie |4 aut | |
| 700 | 1 | |a Solis, Vincente Joel |4 aut | |
| 700 | 1 | |a Denneny, Emma |4 aut | |
| 700 | 1 | |a Evans, Rebecca |4 aut | |
| 700 | 1 | |a Temkin, Mia I. |4 aut | |
| 700 | 1 | |a De Vasconcelos, Nathalia |4 aut | |
| 700 | 1 | |a Aramburu, Iker Valle |4 aut | |
| 700 | 1 | |a Hoving, Dennis |4 aut | |
| 700 | 1 | |a Basire, Donna |4 aut | |
| 700 | 1 | |a Crissell, Tracey |4 aut | |
| 700 | 1 | |a Guinto, Jesusa |4 aut | |
| 700 | 1 | |a Webb, Alison |4 aut | |
| 700 | 1 | |a Esmail, Hanif |4 aut | |
| 700 | 1 | |a Johnston, Victoria |4 aut | |
| 700 | 1 | |a Last, Anna |4 aut | |
| 700 | 1 | |a Rampling, Thomas |4 aut | |
| 700 | 1 | |a Helbig, Elisa Theresa |4 aut | |
| 700 | 1 | |a Lippert, Lena |4 aut | |
| 700 | 1 | |a Kurth, Florian |4 aut | |
| 700 | 1 | |a Williams, Bryan |4 aut | |
| 700 | 1 | |a Flynn, Aiden |4 aut | |
| 700 | 1 | |a Lukey, Pauline T |4 aut | |
| 700 | 1 | |a Birault, Veronique |4 aut | |
| 700 | 1 | |a Papayannopoulos, Venizelos |0 (orcid)0000-0002-3741-8190 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 19. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.04.14.22272888 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 01 | ||